XENE earnings analysis
What we found in XENE's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Xenon Pharmaceuticals reported Q1 2026 results with no revenue generated, significantly falling short of the estimated $3.8 million. The reported EPS of -$1.17 was better than the anticipated -$1.19. The company plans to submit a New Drug Application for azetukalner in Q3 2026, highlighting progress in clinical trials despite ongoing financial losses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Reported EPS Better Than Expected
- The company reported EPS of -$1.17, beating the expected -$1.19.
- Significant Increase in R&D Expenses
- R&D expenses surged to $88.5 million from $61.2 million year-over-year, a 44.7% increase.
- Strong Cash Position Maintained
- As of March 31, 2026, cash and cash equivalents totaled $1,339.6 million.
- Delay of Revenue Generation
- The company recognized nil revenue in Q1 2026 compared to $7.5 million in Q1 2025.
- Regulatory Submission Anticipated
- Xenon expects to file a New Drug Application for azetukalner in Q3 2026.
- R&D Pipeline Focus on Azetukalner
- Continued focus on azetukalner, with ongoing Phase 3 clinical studies.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No Revenue Generated in Q1 2026
- The company reported $0 in revenue for Q1 2026, down from $7.5 million in Q1 2025.
- Increased Operating Loss
- Net loss for Q1 2026 increased to $102.3 million compared to $65.0 million in Q1 2025.
- Dependency on Successful Regulatory Approval
- The company's future growth relies on regulatory approval for azetukalner, with no previous market experience.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.17
What they said about what is next.
Xenon anticipates submission of a New Drug Application (NDA) for azetukalner in Q3 2026.
The filing reads worse than the one before it.
What came before.
- 10-K · February 26, 2026
- Xenon remains a late-stage neuroscience biopharma centered on azetukalner, with multiple Phase 3 programs progressing (X-TOLE2 enrollment complete at 380 patients and topline readout anticipated in the first half of…
- 10-Q · November 3, 2025
- Xenon Pharmaceuticals reported a net loss of $90.9 million for Q3 2025, slightly worse than the $62.8 million loss in the comparable quarter last year. Revenue remains at $0, while EPS also declined, reflecting…
- 10-Q · August 8, 2024
- Xenon reported a net loss of $57,924k for the three months ended June 30, 2024 (EPS -$0.75), widening vs. the prior-year quarter loss of $47,461k (EPS -$0.72). Operating expenses rose to $69,104k driven by higher R&D of…
- 10-K · February 29, 2024
- Xenon positions itself as a neuroscience-focused biotech building a proprietary pipeline led by XEN1101 for epilepsy and MDD, leveraging discovery capabilities and selective collaborations. The filing highlights robust…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing XENE makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever